Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $115
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $111 to $115.
Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $111 to $115.